Figure 3.Validation of prognostic implications of CCL19 expression for PFS in BRCA patients across independent cohorts. With 4929 BRCA samples in total, PFS analysis of independent cohorts was performed.
Figure 3 — CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers | Aging
